Cellectar Biosciences Inc. has inked a new chief financial officer, it announced Thursday.
The Florham Park-based biopharmaceutical company said it has appointed Dov Elefant, a seasoned biotechnology executive, as its new CFO, effective Sept. 10.
“We are excited to have Dov join the Cellectar team. He brings tremendous industry experience as a seasoned financial executive having served as CFO for three publicly traded companies in the life sciences sector,” James Caruso, CEO and president of Cellectar, said. “Throughout his long career, Dov has demonstrated outstanding leadership and has achieved many significant accomplishments. I am certain his deep industry expertise will be a tremendous asset as we advance the company and deliver key milestones in the coming months.”
Elefant, who has more than 20 years of experience in corporate finance and operational leadership, previously served as CFO at several companies, most recently at Akari Therapeutics. Before that, he was CFO at Celsus Therapeutics and at Althera Medical Ltd.
“I am thrilled to join the Cellectar management team and be part of its exciting journey. The PDC platform technology is impressive and CLR-131 is a promising therapy with the potential to provide meaningful treatment options in liquid and solid tumors for both adult and pediatric patients. I look forward to contributing to the Company’s success and continued growth,” Elefant said.
Elefant has also served as a consultant for a number of businesses as well as corporate controller at Lev Pharmaceuticals through its acquisition by ViroPharma.
